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Abstract 
Histiocytic Sarcoma (HS) is a rare hematologic 
malignancy that belongs to the group of histiocytic 
and dendritic cell neoplasms. The causal etiology of 
HS is unknown. The clinical course is very 
aggressive. 
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Clinics and pathology 
Disease 
Histiocytic Sarcoma (HS) is a rare hematologic 
malignancy that belongs to the group of histiocytic 
and dendritic cell neoplasms. The defining 
morphologic and phenotypic features of HS 
neoplastic cells are similar to mature tissue 
histiocytes (Pileri SA et al., 2002). The causal 
etiology of HS is unknown (no genetic or 
environmental factors are well described) HS could 
arise as a secondary malignancy, in the context of 
evolution from low-grade B-cell lymphoma.  In 
these cases both disorders are clonally related 
(Feldman AL et al., 2004; Feldman AL et al., 2008; 
Wang E et al., 2010). An association with germ cell 
tumors has been reported (Song SY et al., 2005). The 
HS often develops solitary or multifocal extranodal 
tumors (gastrointestinal tract, soft tissue, skin or 
other organ damage). The clinical course is very 
aggressive and overall survival (OS) of 2 years has 
been reported (Ansari J et al., 2016). There is no 
standard treatment; in disseminated forms systemic 
therapy (chemotherapy) has an important role, 
whereas surgical resection with or without adjuvant 
radiotherapy reaches better outcomes in localized 
masses (Facchetti F et al., 2017; Kommalapati A et 
al., 2018). 
Phenotype/cell stem origin 
PATHOGENESIS is poorly understood but in the 
last decade some advances had been made.  
There is a clear association between various 
hematological neoplasms (especially those of B cell 
origin) and HS. To explain this evolution three 
mechanisms have been proposed (Wang E et al., 
2010): transdifferentiation, where B cells change 
phenotypically but remains its genotypic features 
(Feldman AL et al., 2008), dedifferentiation where B 
cells regresses to early progenitors stage suffering 
afterward a new differentiation (not evidence in HS 
cases), and a common neoplastic progenitor 
(Feldman AL et al., 2004).  
Transdifferentiation represents the most probably 
and well described pathway since some studies have 
demonstrated cases of HS (subsequent or concurrent 
with these neoplasms) showing clonal 
immunoglobulin heavy chain (IGH) and/or T-cell 
receptor (TCR) gene rearrangements, providing the 
evidence of a common clonal origin (Feldman AL et 
al., 2008; Wang E et al., 2010).  
BRAF V600E mutation has also been observed in 
HS, being activation of RAS/RAF pathway another 
possible malignant transformation mechanism (Go 
H et al., 2014). Furthermore, alterations in KMT2D 
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(MLL2), also described in HS, have a role in its 
pathogenesis, in particular, in chromatin 
dysregulation (Hung YP et al., 2017). 
Epidemiology 
HS is a very rare disorder that affects people at any 
age with predominance in adults and male gender. 
Recent studies establish a median age at diagnosis of 
63 years and lower incidence in African Americans 
than Caucasians (Kommalapati A et al., 2018). 
Clinics 
The vast majority of patients present with single or 
multifocal tumors, mostly affecting lymph nodes, 
skin, gastrointestinal tract, soft tissues, spleen, liver 
or bone (Takahashi E et al., 2013). Thus symptoms 
related to those targets organs (eg, intestinal 
obstruction, cytopenias or hepatosplenomegaly) 
could be presenting symptoms (Dalia S et al., 2014). 
Consequently, the clinical presentation of HS is 
diverse. Patients may have other systemic symptoms 
like fever, fatigue, weight loss or low blood counts 
(Ansari J et al., 2016; Takahashi E et al., 2013). Skin 
involvement can be seen in a variety manifestations, 
from a rash to tumors that can arise in extremities or 
the trunk. 
Pathology 
HS shows a diffuse growth pattern involving nodal 
or extranodal tissue; nevertheless sinusoidal or 
parenchymal pattern predominates if there is a 
lymph node, liver/spleen or bone marrow infiltration 
(Skala SL et al., 2018). Tumor cells are large and 
pleomorphic, with abundant eosinophilic cytoplasm 
that may enclose vacuoles. The nuclei, also 
pleomorphic, usually presents prominent nucleoli 
and in some cases multinucleation. A dense 
inflammatory background, confirmed by 
lymphocytes and neutrophils, is observed (Hung YP 
et al., 2017). Images of hemophagocytosis and 
necrosis have also been described.  
IMMUNOPHENOTYPE It provides an important 
role, both to confirm the histiocytic nature of 
neoplasms cells and to dismiss other not well-
differentiated tumors. Cells typically express CD68, 
CD4, lysozyme, and CD163 as specific markers of 
histiocytic differentiation (Dalia S et al., 2014). 
However, lysozyme and CD68 can be expressed in 
some other tumors like non-Hodgkin lymphomas 
and melanomas/carcinomas, respectively. 
Therefore, CD163 (membranous and cytoplasmatic 
pattern) is a more specific marker for the diagnosis 
of HS (Hung YP et al., 2017; Skala SL et al., 2018). 
It remains crucial the exclusion of poorly 
differentiated neoplasms as carcinomas, melanomas, 
hematological disorders (not specific B, T and 
myeloid cell markers either Langerhans and 
dendritic cell markers) (Hung YP et al., 2017). The 
Ki-67 index is usually between 5-50% (Skala SL et 
al., 2018). Recent studies have reported the 
expression of the programmed death ligand 1 (PD-
L1) in cases of HS, and its potential therapeutic 
target (Facchetti F et al., 2017). 
Genes 
There have not been reported characteristic 
molecular alterations specific for HS. Despite, there 
is a subset of HS that share molecular aberrations 
with other primary hematopoietic malignancies 
(being IGH and TCR gene rearrangements a case in 
point). Moreover, clonal IGH gene rearrangements 
have been described in sporadic HS (Chen W et al., 
2009).  
Application of Next Generation Sequencing (NGS) 
has improved the landscape of molecular features in 
HS.  
Using NGS, recurrent alterations in KMT2D 
(MLL2), on chromosome 12q13.2, have been 
characterized.  
This gene is involved in chromatin regulation and 
had also been reported in other hematologic 
malignancies (Hung YP et al., 2017).  
Nevertheless, further studies are necessary to 
confirm those results and shed light on this matter. 
Treatment 
DIAGNOSIS Due to its low incidence and the 
possibility of overlapping of morphological and 
immunophenotypical features with other disorders, 
the diagnosis of HS is difficult. It is made based upon 
the evaluation of a biopsy specimen from the site of 
involvement.  
The diagnostic key lies in the cytologic features and 
the advances in the recognition of histiocytic cell 
markers (CD 68, CD163 and lysozyme), mentioned 
above (Ansari J et al., 2016; Facchetti F et al., 2017). 
Certainly, clinical context also has an important 
relevance.  
Imaging studies, as computed tomography or 
combined positron emission tomography, and bone 
marrow biopsy, could be useful to determinate the 
extension of the disease and the end organ damage 
(Dalia S et al., 2014).  
The differential diagnosis must include: non-
Hodgkin lymphomas, Langerhans cell histiocytosis, 
others histiocytic and dendritic cell neoplasms, 
carcinomas, melanomas, sarcomas  
There is no standardized treatment for HS and the 
extent of the disease usually determines the 
therapeutic option among systemic chemotherapy, 
surgery and/or radiotherapy (Facchetti F et al., 2017; 
Kommalapati A et al., 2018). Traditionally, in cases 
of unifocal disease surgical resection with or without 
radiotherapy is employed; whereas systemic 
chemotherapy is the choice in multifocal disease. 
Regimens like CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisone), ICE 
(ifosfamide, cisplatin, etoposide) or ABVD 
(doxorubicin, bleomycin, vinblastine, dacarbazine) 
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are often used (Facchetti F et al., 2017; Kommalapati 
A et al., 2018). The role of adjuvant radiation therapy 
can be considered since it can reduce recurrence 
rates (Dalia S et al., 2014).  
In a study using the National Cancer Database 
(NCDB) 330 cases of HS were reviewed 
(Kommalapati A et al., 2018). It was reported an 
improved OS in those HS cases where localized 
therapy (surgery either alone or with radiotherapy) 
was performed compared to systemic therapy. It has 
also been observed poorer outcomes (in terms of OS) 
when the hematopoietic or reticuloendothelial 
system was involved, despite the use of 
chemotherapy regimens (Kommalapati A et al., 
2018).  
The development of new therapies in this disease is 
necessary, new-targeted treatments are being used, 
like inhibitors of PD-L1 in those cases when it is 
expressed (Facchetti F et al., 2017) or tyrosine kinase 
inhibitors (as vemurafenib) if BRAF mutations are 
presented (Ansari J et al., 2016). 
Prognosis 
HS is an aggressive entity with an OS (in treated 
cases) that frequently does not get prolonged further 
than 2 years (Ansari J et al., 2016; Skala SL et al., 
2018). Without treatment, survival is measured in 
months. Kommalapati A et al., in his studio of 330 
HS cases, reported an OS of 6 months for the entire 
cohort, and described some possible prognostic 
factors: age, site of presentation, comorbidities, and 
therapy received (Kommalapati A et al., 2018). 
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